Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 8/20 | 0.52 |
| ▸ | CA2 | P00918 | 8/20 | 0.52 |
| ▸ | CA12 | O43570 | 5/20 | 0.52 |
| ▸ | CA9 | Q16790 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | CCNC | P24863 | 1/20 | 0.41 |
| ▸ | CDK8 | P49336 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 2/20 | 0.41 |
| ▸ | CNR2 | P34972 | 2/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6757589 | 1.00 | CA1 (0.52) | CA1CA2CA12CA9ALDH1A1 | |
| SCHEMBL21071071 | 1.00 | CA1 (0.52) | CA1CA2CA12CA9ALDH1A1 | |
| SCHEMBL26102679 | 1.00 | CA1 (0.52) | CA1CA2CA12CA9ALDH1A1 | |
| SCHEMBL14745101 | 1.00 | CA1 (0.52) | CA1CA2CA12CA9ALDH1A1 | |
| SCHEMBL21531171 | 1.00 | CA1 (0.52) | CA1CA2CA12CA9ALDH1A1 | |
| SCHEMBL31235782 | 1.00 | CA1 (0.52) | CA1CA2CA12CA9ALDH1A1 | |
| SCHEMBL8073830 | 1.00 | CA1 (0.52) | CA1CA2CA12CA9ALDH1A1 | |
| SCHEMBL17162059 | 0.94 | CA1 (0.49) | CA1CA2CA12CA9ALDH1A1 | |
| SCHEMBL22326317 | 0.93 | CA1 (0.51) | CA1CA2CA12CA9ALDH1A1 | |
| SCHEMBL791306 | 0.92 | CA2 (0.56) | CA1CA2CA12CA9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114447433-A | Electrolyte solution for lithium secondary battery and lithium secondary battery comprising the same | 现代自动车株式会社 | 2022-05-06 | — | — | CN | claimed |
| EP-4714949-A1 | NOVEL COMPOUNDS CAPABLE OF INDUCING OSTEOGENIC DIFFERENTIATION | AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2026-03-25 | — | — | EP | disclosed |
| US-20260078097-A1 | PIPERAZINE COMPOUNDS | SPARK THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-20260055097-A9 | NRF2 PROTEIN DEGRADERS | GANYMEDE ONCOLOGY INC (US) | 2026-02-26 | — | — | US | disclosed |
| US-20260034228-A1 | DRUG DELIVERY SYSTEM FOR TREATING DISEASE | SDG LLC (US) | 2026-02-05 | — | — | US | disclosed |
| US-20250339566-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN | UNIV ANTWERPEN (BE) | 2025-11-06 | — | — | US | disclosed |
| US-12377154-B2 | Drug delivery system for treating disease | SDG, LLC (US) | 2025-08-05 | — | — | US | disclosed |
| US-20250145611-A1 | NRF2 PROTEIN DEGRADERS | GANYMEDE ONCOLOGY, INC. | 2025-05-08 | — | — | US | disclosed |
| EP-4543439-A2 | NRF2 PROTEIN DEGRADERS | Ganymede Oncology, Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| EP-4531932-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN | Universiteit Antwerpen (BE) | 2025-04-09 | — | — | EP | disclosed |
| US-20070087400-A1 | Covalent tethering of functional groups to proteins and substrates therefor | PROMEGA CORPORATION | 2007-04-19 | — | — | US | disclosed |
| WO-2006050942-A1 | MACROLONES - AMINO SUBSTITUTED QUINOLONES | GLAXO GROUP LIMITED (GB) | 2006-05-18 | — | — | WO | disclosed |
| WO-2006050941-A1 | MACROLONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2006-05-18 | — | — | WO | disclosed |
| WO-2006050943-A1 | MACROLONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2006-05-18 | — | — | WO | disclosed |
| US-20030138432-A1 | Selective cellular targeting: multifunctional delivery vehicles, multifunctional prodrugs, use as antineoplastic drugs | DRUG INNOVATION & DESIGN, INC. | 2003-07-24 | — | — | US | disclosed |
| EP-1255567-A1 | SELECTIVE CELLULAR TARGETING: MULTIFUNCTIONAL DELIVERY VEHICLES | Drug Innovation & Design, Inc. (US) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001036003-A2 | SELECTIVE CELLULAR TARGETING: MULTIFUNCTIONAL DELIVERY VEHICLES | DRUG INNOVATION & DESIGN, INC. (US) | 2001-05-25 | — | — | WO | disclosed |
| US-6171520-B1 | Reagents for labeling SH groups, process for the preparation of them and method for labeling with them | SS PHARMACEUTICAL CO., LTD. (JP) | 2001-01-09 | — | — | US | disclosed |
| EP-0844246-A1 | REAGENTS FOR LABELING SH GROUPS, PROCESS FOR THE PREPARATION OF THEM, AND METHOD FOR LABELING WITH THEM | SS Pharmaceutical Co., Ltd. (JP) | 1998-05-27 | — | — | EP | disclosed |
| WO-1997020821-A1 | HETEROARYL DERIVATIVES | NOVARTIS AG (CH) | 1997-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070087400-A1 | Covalent tethering of functional groups to proteins and substrates therefor | WASF2, NOTUM, YIPF5 | CA1 3873/4885CA2 4389/4885CA12 4286/4885 |
| US-20030138432-A1 | Selective cellular targeting: multifunctional delivery vehicles, multifunctional prodrugs, use as antineoplastic drugs | PAICS, ABCB1, ABCG2 | CA1 1757/4885CA2 1014/4885CA12 1525/4885 |
| US-20250339566-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN | FIBP, FGF1, FGFR1 | CA1 3015/4885CA2 362/4885CA12 3894/4885 |
| US-20260034228-A1 | DRUG DELIVERY SYSTEM FOR TREATING DISEASE | HM13, HCAR2, HBZ | CA1 713/4885CA2 663/4885CA12 155/4885 |
| US-12377154-B2 | Drug delivery system for treating disease | HPGDS, VHL, HPSE | CA1 1007/4885CA2 636/4885CA12 60/4885 |
| US-20260078097-A1 | PIPERAZINE COMPOUNDS | NPC1, LPAR5, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | CA1 3366/4885CA2 1269/4885CA12 2212/4885 |
| US-20260055097-A9 | NRF2 PROTEIN DEGRADERS | KEAP1, NFE2L2, NFE2 | CA1 3789/4885CA2 2041/4885CA12 3947/4885 |
| US-20250145611-A1 | NRF2 PROTEIN DEGRADERS | KEAP1, NFE2L2, NFE2 | CA1 4531/4885CA2 3954/4885CA12 4622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.